Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight.
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid.
Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.
Did Novo Nordisk Just Say "Checkmate" to Pfizer? These two leading drugmakers are fighting over a promising GLP-1 candidate.
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal.
Meet the 7% Yield Dividend Stock That Could Soar in 2026 This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.
Is It Time to Dump Your Shares of Pfizer? Pfizer stock has dropped 50% over the past three years.
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company.
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.
The market is filled with gapping stocks in Thursday's session. Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
2 High-Yield Stocks With Fresh Catalysts Income investors can capture yields above 5% from companies executing business transformations.
